1.Bridgses, CB, Harper, SA, Fukuda, K, Uyeki, TM, Cox, NJ, Singleton, JA. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:1–34.
2.Harper, SA, Fukuda, K, Cox, NJ, Bridges, CB. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003;52:1–8.
3.Belshe, RB, Mendelman, PM, Treanor, J, et al.The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338:1405–1412.
4.Belshe, RB, Gruber, WC, Mendelman, PM, et al.Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the. vaccine. J Pediatr 2000;136:168–175.
5.Nichol, KL, Mendelman, PM, Mallon, KP, et al.Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA 1999;282:137–144.
6.Medlmmune Vaccines, Inc. Influenza Virus Vaccine, Live Intranasal FluMist [package insert]. Gaithersburg, MD: Medlmmune Vaccines, Inc.; 2003.
7.Anonymous. Flu mystified: hospitals are in a fog. of live viral vaccine issues. Hospital Infection Control 2004;31:1–5.
8.Vesikari, T, Karvonen, A, Korhonen, T, et al. A randomized, double-blind, placebo-controlled trial of the safety, transmissibility an. phenotypic stability of a live, attenuated, cold-adapted influenza virus vaccine (CAIV-T) in children attending da. care. Presented at th. 41st Annual Interscience Conference on Antimicrobial Agents an. Chemotherapy; December 16-19, 2001; Chicago, IL. Abstract G-450.
9.King, JC Jr, Treanor, J, Fast, PE, et al.Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000;181:725–728.
10.Belshe, RB, Swierkosz, EM, Anderson, EL, Newman, FK, Nugent, SL, Maassab, HF. Immunization of infants and. young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine. J Infect Dis 1992;165:727–732.
11.Keitei, WA, Couch, RB, Quarles, JM, Cate, TR, Baxter, B, Maassab, HF. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993;167:305–311.
12.Meguro, H, Bryant, JD, Torrence, AE, Wright, PF. Canine kidney cell line for isolation of respiratory viruses. J Clin Microbiol 1979;9:175–179.
13.Boyce, TG, Gruber, WC, Coleman-Dockery, SD, et al.Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999;18:82–88.
14.Snyder, MH, Banks, S, Murphy, BR. Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay. J Clin Microbiol 1988;26:2034–2040.
15.Hierholzer, JC, Suggs, MT. Standardized viral hemagglutination and hemagglutination-inhibition tests: I. Standardization of erythrocyte suspensions. Appl Microbiol 1969;18:816–823.
16.Hierholzer, JC, Suggs, MT, Hall, EC. Standardized viral hemagglutination and hemagglutination-inhibition tests: II. Description and statistical evaluation. Appl Microbiol 1969;18:824–833.
17.Crowe, JE Jr, Sannella, EC, Pfeiffer, S, et al.CD154 regulates primate humoral immunity to influenza. Am J Transplant 2003;3:680–688.
18.Plotkin, SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis. J 2001;20:63–75.
19.Treanor, J, Wright, PF. Immune correlates of protection against influenza in the. human challenge model. Dev Biol (Basel) 2003;115:97–104.
20.Keitei, WA, Couch, RB, Cate, TR, Six, HR, Baxter, BD. Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge. J Infect Dis 1990;161:22–26.
21.Clements, ML, Snyder, MH, Sears, SD, Maassab, HF, Murphy, BR. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers. J Infect Dis 1990;161:869–877.
22.Sears, SD, Clements, ML, Betts, RF, Maassab, HF, Murphy, BR, Snyder, MH. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988;158:1209–1219.
23.Reeve, P, Pibermann, M, Bachmayer, H, et al.Studies in man with a cold-recombinant live influenza B virus vaccine. J Med Virol 1982;9:1–9.
24.Mortiz, AJ, Kunz, C, Hofman, H, Liehl, E, Reeve, P, Maassab, HF. Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus: II. Evaluation in adult volunteers. J Infect Dis 1980;142:857–860.
25.King, JC Jr, Fast, PE, Zangwill, KM, et al.Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001;20:1124–1131.
26.Gruber, WC, Belshe, RB, King, JC, et al.Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. J Infect Dis 1996;173:1313–1319.
27.Edwards, KM, King, JC, Steinhoff, MC, et al.Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. J Infect Dis 1991;163:740–745.
28.Feldman, S, Wright, PF, Webster, RG, et al.Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus. J Infect Dis 1985;152:1212–1218.
29.Wright, PF, Okabe, N, McKee, KT Jr, Maassab, HF, Karzon, DT. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982;146:71–79.
30.Murphy, BR, Clements, ML, Tierney, EL, Black, RE, Stienberg, J, Chanock, RM. Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers. J Infect Dis 1985;152:225–229.
31.Cha, TA, Kao, K, Zhao, J, Fast, PE, Mendelman, PM, Arvin, A. Genotypie stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 2000;38:839–845.
32.Belshe, RB. Current status of live attenuated influenza virus vaccine in the US. Virus Res 2004;103:177–185.
33.Gruber, WC, Hinson, HP, Holland, KL, Thompson, JM, Reed, GW, Wright, PF. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J Infect Dis 1993;168:1282–1285.
34.Sendi, P, Locher, R, Bucheli, B, Battegay, M. Intranasal influenza vaccine in a working population. Clin Infect Dis 2004;38:974–980.
35.Harper, SA, Fukuda, K, Uyeki, TM, Cox, NJ, Bridges, CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53:1–40.